International Exclusive Partnership Brings Significant Scientific
MARKHAM, ON, April 7, 2014 /CNW/ - MedReleaf™, a licensed producer and
supplier of medical cannabis, is tapping into its exclusive partnership
with world-class leader Tikun Olam™, to bring Canadians an offering of
medical cannabis varieties unmatched by any other producer licensed
through Health Canada's Marihuana for Medical Purposes Regulations. Tikun Olam is the first and largest government-approved producer of
medical cannabis in Israel - one of the most progressive medical
cannabis markets in the world.
"Our partnership with Tikun Olam gives us a significant scientific
advantage," said MedReleaf CEO, Neil Closner. "We have access to
treatment data from more than 7,000 Tikun Olam patients that will give
us great insight into the effectiveness and efficacy of various strains
and in turn, an enhanced ability to work with patients and physicians
to create the most beneficial treatment protocols. The partnership also
provides us with exclusive access to a vast array of proprietary
medical cannabis varieties."
Two of the many unique proprietary varieties of medical cannabis that
MedReleaf will grow and make available to Canadians are Erez™, the best-selling variety in Israel, and AviDekel™. Erez, with its high tetrahydrocannabinol (THC) content, is well known for
treating sleep disorders and managing pain, nausea, inflammation, and
indigestion. AviDekel, a sativa-dominant strain, contains very high levels of cannabidiol
(CBD) and almost no THC. CBD is a non-psychoactive compound found in
cannabis that has been shown to have a positive impact on disorders
such as multiple sclerosis, arthritis and epilepsy, amongst other
MedReleaf anticipates particular interest in AviDekel. Its exceptionally high levels of CBD (among the highest in Canada)
with almost no THC contains similar properties to the variety of
medical cannabis in the United States, known as Charlotte's Web, named after Charlotte Figi who experienced a reduction of her
epileptic seizures after her first dose. World-renowned CBD expert,
Professor of Immunology Ruth Gallily of the Hebrew University of
Jerusalem is currently conducting laboratory research on all of Tikun
Olam's unique CBD-rich cannabis strains to further understand their
potential therapeutic applications.
"Tikun Olam has dedicated its work, time and passionate efforts to
examining the efficacy and safety of our products; we do this through
continued follow-up with patients, laboratory studies (both in vitro
and in vivo as well as retrospective studies), surveys and clinical
research," said Maayan Weisberg, Director of Marketing and Business
Development. "We are pleased to collaborate with MedReleaf through this
partnership and very much look forward to helping Canadian patients and
physicians better understand the many benefits of medical cannabis."
MedReleaf, in partnership with Tikun Olam, is currently collaborating on
more than two-dozen cannabis related research studies (lab
and clinical) with doctors and professors at eight leading hospitals in
Israel including the Hadassah Medical Center in Jerusalem, Wolfson
Medical Center in Holon, Sheba Medical Center at Tel Hashomer, Meir
Medical Center in Kfar Saba and Tel Aviv Sourasky Medical Center.
MedReleaf is interested in conducting additional research in Canada and
is seeking physician partners for these initiatives.
MedReleaf™ is a Canadian-owned and operated producer and distributor of
medical grade cannabis. The company operates a 55,000 square foot
state-of-the-art facility in Markham, Ontario. Its leadership team
includes highly skilled and expert professionals who have more than 100
years of combined experience treating patients and working with
cannabis. They have extensive backgrounds in business, molecular plant
genetics, biotechnology, horticulture, clinical laboratory management
and operations. MedReleaf is dedicated to improving the quality of life
for patients across Canada by providing them with a broad range of the
finest quality varieties anywhere in the world. MedReleaf obtained its
license from Health Canada in February 2014.
SOURCE: MedReleaf Corp.
For further information:
GoldFenix Communications & Associates
GoldFenix Communications & Associates